Muhammad Yasin Sheikh MD FACP, FACG, AGAF
Hepatology & Liver Transplantation, Nutrition
President, Fresno Clinical Research Center Vice President, Advanced Gastroenterology & Hepatology Associates
Join to View Full Profile
7102 N Fresno StSuite 108 & 101Fresno, CA 93720
Phone+1 559-712-6199
Fax+1 559-298-7408
Dr. Sheikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Muhammad Sheikh is a gastroenterologist based in Fresno, CA, with subspecialties in hepatology, liver transplantation, and nutrition. He completed his residency in internal medicine at Indiana University School of Medicine and pursued gastroenterology fellowships at the University of Louisville and Beth Israel Deaconess Medical Center. As Vice President at the Community Foundation since 2016, he has extensive experience in hepatology and various liver diseases. Dr. Sheikh has published several works on liver disease and NASH and has contributed to numerous clinical trials related to these conditions. His professional accolades include fellowships from the American College of Physicians and the AGA, as well as the Laureate Award from the American College of Physicians in 2012.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Gastroenterology, 1997 - 1998
University of Louisville School of MedicineFellowship, Gastroenterology, 1994 - 1997
Indiana University School of MedicineResidency, Internal Medicine, 1991 - 1994
Dow University of Health SciencesClass of 1982
Certifications & Licensure
CA State Medical License 1998 - 2028
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Fellow American College of Physician
- Fellow AGA
- Laureate Award from American College of Physicians- 2012
Clinical Trials
- Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Start of enrollment: 2014 Sep 18
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2015 Jul 31
- Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Publications & Presentations
PubMed
- 77 citationsResults from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.Arun J Sanyal, Vlad Ratziu, Rohit Loomba, Quentin M Anstee, Kris V Kowdley
Journal of Hepatology. 2023-11-01 - 81 citationsAldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy
The Lancet. Gastroenterology & Hepatology. 2022-07-01 - 9 citationsRedefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.Yasser Fouad, Melissa Palmer, Minjun Chen, Arie Regev, Rajarshi Banerjee
Journal of Clinical and Translational Hepatology. 2022-04-28
Committees
- Member, Sante Credentialing committee 2017 - 2020
Professional Memberships
- Fellow
Other Languages
- Urdu
External Links
- Fresno Clinical Research Centerhttps://www.facebook.com/fresnocrc/?ref=bookmarks
- Fresno Clinical Research Centerhttps://www.fresnocrc.com/
- Advanced Gastroenterology & Hepatology Associateshttps://www.aghafresno.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
